F9 | Coagulation factor IX | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FCGR2A | Fc fragment of IgG, low affinity IIa, receptor (CD32) | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
FCGR2B | Fc fragment of IgG, low affinity IIb, receptor (CD32) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
FCGR3A | Fc fragment of IgG, low affinity IIIa, receptor (CD16a) | CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FGA | Fibrinogen alpha chain | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
FGFR1 | Fibroblast growth factor receptor 1 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Expressed in all |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FLT1 | Fms-related tyrosine kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enriched |
FN1 | Fibronectin 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
FSHR | Follicle stimulating hormone receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Group enriched |
GABBR1 | Gamma-aminobutyric acid (GABA) B receptor, 1 | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
GABRA1 | Gamma-aminobutyric acid (GABA) A receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABRA2 | Gamma-aminobutyric acid (GABA) A receptor, alpha 2 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
GABRA4 | Gamma-aminobutyric acid (GABA) A receptor, alpha 4 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
GABRA5 | Gamma-aminobutyric acid (GABA) A receptor, alpha 5 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABRB1 | Gamma-aminobutyric acid (GABA) A receptor, beta 1 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
GABRB3 | Gamma-aminobutyric acid (GABA) A receptor, beta 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GABRE | Gamma-aminobutyric acid (GABA) A receptor, epsilon | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
GABRG2 | Gamma-aminobutyric acid (GABA) A receptor, gamma 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GABRG3 | Gamma-aminobutyric acid (GABA) A receptor, gamma 3 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GABRP | Gamma-aminobutyric acid (GABA) A receptor, pi | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GABRR1 | Gamma-aminobutyric acid (GABA) A receptor, rho 1 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GANAB | Glucosidase, alpha; neutral AB | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
GCGR | Glucagon receptor | FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
GHR | Growth hormone receptor | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
GHRHR | Growth hormone releasing hormone receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
GLRB | Glycine receptor, beta | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
GRM5 | Glutamate receptor, metabotropic 5 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
HTR3A | 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Group enriched |
ICAM1 | Intercellular adhesion molecule 1 | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IDE | Insulin-degrading enzyme | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
IFNAR1 | Interferon (alpha, beta and omega) receptor 1 | Cancer-related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IFNG | Interferon, gamma | Cancer-related genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IFNGR1 | Interferon gamma receptor 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IFNGR2 | Interferon gamma receptor 2 (interferon gamma transducer 1) | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IL11RA | Interleukin 11 receptor, alpha | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IL1R1 | Interleukin 1 receptor, type I | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL3RA | Interleukin 3 receptor, alpha (low affinity) | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
IL6R | Interleukin 6 receptor | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
ITGA4 | Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Mixed |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
ITGB3 | Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
KCNN4 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
LHCGR | Luteinizing hormone/choriogonadotropin receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LIPF | Lipase, gastric | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
LPL | Lipoprotein lipase | Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
M6PR | Mannose-6-phosphate receptor (cation dependent) | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
MET | Met proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |